Pharmaceuticals

Rare Gastrointestinal Diseases Treatment Market Research: Growth Projections and Trends 2030

February 24, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the rare gastrointestinal diseases treatment market from 2026–2035 with trusted insights from The Business Research Company

How much is the Rare Gastrointestinal Diseases Treatment Market valued at in 2026, and what valuation is forecast for 2030?

The rare gastrointestinal diseases treatment market size has experienced robust expansion in recent years. It is projected to grow from $1.45 billion in 2025 to $1.53 billion in 2026, at a compound annual growth rate (CAGR) of 5.9%. The expansion during the historic period can be attributed to factors such as increasing recognition of rare GI disorders, the expansion of specialty gastroenterology centers, the availability of immunosuppressive and anti-inflammatory drugs, rising clinical research activity, and improved diagnostic accuracy.

The rare gastrointestinal diseases treatment market is set for significant expansion in the coming years, with projections indicating it will reach $1.91 billion by 2030, driven by a compound annual growth rate (CAGR) of 5.6%. This anticipated growth is attributable to factors such as the increasing development of orphan drugs, rising investments in rare disease research, the growing adoption of biologic therapies, the expansion of precision medicine approaches, and enhanced patient access to advanced treatments. Major trends expected during this forecast period encompass the increasing embrace of targeted biologic therapies, a rising focus on personalized treatment protocols, the growing use of advanced diagnostic devices, the expansion of enzyme replacement therapies, and the enhanced integration of digital patient monitoring.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28317&type=smp

What Drivers Are Influencing The Growth Of The Rare Gastrointestinal Diseases Treatment Market?

The anticipated increase in diagnostic testing is poised to drive the expansion of the rare gastrointestinal diseases treatment market. Diagnostic tests are medical procedures conducted to identify, confirm, or monitor illnesses, health conditions, or infections in individuals. The escalating need for these tests primarily stems from greater understanding of the importance of detecting diseases early, leading to prompt treatments and improved patient health. Such testing supports the treatment of rare gastrointestinal diseases by facilitating the early and precise identification of root conditions. It assists in pinpointing distinct disease mechanisms, backing tailored treatment strategies, and enhancing patient recovery through quick action. For example, data from December 2024 released by the National Health Service, a UK-based government agency, indicated that diagnostic tests performed reached 2,544,809 in 2024, an increase from 2,312,030 in 2023. Consequently, the surge in diagnostic testing is fueling the expansion of the rare gastrointestinal diseases treatment market.

How Is The Rare Gastrointestinal Diseases Treatment Market Organized Into Various Segments?

The rare gastrointestinal diseases treatment market covered in this report is segmented –

1) By Type: Drugs, Device

2) By Route Of Administration: Oral, Intravenous (IV) Or Injectable, Subcutaneous, Other Routes Of Administration

3) By Application: Eosinophilic Gastroenteritis, Hercksprung’s Disease, Chronic Intestinal Pseudo-Obstruction

4) By End User: Hospitals, Research Institutes, Other End Users

Subsegments:

1) By Drugs: Anti-Inflammatory Drugs, Immunosuppressive Agents, Biologic Therapies, Antibiotics, Proton Pump Inhibitors, Corticosteroids, Enzyme Replacement Therapies

2) By Devices: Endoscopic Devices, Diagnostic Imaging Systems, Surgical Instruments, Feeding Tubes, Stent Devices, Biopsy Devices

How Are New Market Trends Shaping The Landscape Of The Rare Gastrointestinal Diseases Treatment Market?

Leading companies in the rare gastrointestinal diseases treatment market are concentrating on developing innovative therapies, such as fully human monoclonal antibodies, to target specific disease pathways and enhance patient outcomes. These fully human monoclonal antibodies are laboratory-engineered antibodies, entirely derived from human proteins, designed to precisely target disease-causing molecules. This precision helps to block or modulate them effectively, improving treatment efficacy while also reducing side effects. For instance, in August 2023, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, obtained U.S. Food and Drug Administration (FDA) approval for Veopoz (pozelimab-bbfg) to treat CHAPLE disease, a rare and life-threatening hereditary gastrointestinal disorder. Veopoz operates as a fully human monoclonal antibody engineered to target complement factor C5, assisting in the regulation of the overactive complement system responsible for protein loss and gastrointestinal damage in CHAPLE patients. This targeted mechanism of action addresses the disease’s underlying cause, thereby preventing severe symptoms and potential life-threatening complications.

Who Are The Core Companies Influencing Trends In The Rare Gastrointestinal Diseases Treatment Market?

Major companies operating in the rare gastrointestinal diseases treatment market are Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Bayer AG, Sanofi S.A., Zealand Pharma A/S, Novartis AG, AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Ipsen S.A., PTC Therapeutics Inc., Ironwood Pharmaceuticals Inc., Mirum Pharmaceuticals Inc., Albireo Pharma Inc., Orphalan S.A., Ellodi Pharmaceuticals Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/rare-gastrointestinal-diseases-treatment-global-market-report

Which Regions Are Projected To Dominate The Rare Gastrointestinal Diseases Treatment Market In The Coming Years?

North America was the largest region in the rare gastrointestinal diseases treatment market in 2025. The regions covered in the rare gastrointestinal diseases treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Rare Gastrointestinal Diseases Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=28317&type=smp

Browse Through More Reports Similar to the Global Rare Gastrointestinal Diseases Treatment Market 2026, By The Business Research Company

Rare Diseases Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report

Rare Inflammatory Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-inflammatory-disease-treatment-global-market-report

Gastrointestinal Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drug-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795